Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: ubiquitin specific protease inhibitors - Hybrigenics

Drug Profile

Research programme: ubiquitin specific protease inhibitors - Hybrigenics

Alternative Names: HBX 19,818; HBX 41,108; HBX 96,819; USP inhibitors - Hybrigenics; USP8 inhibitors - Hybrigenics

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hybrigenics
  • Class Small molecules
  • Mechanism of Action Ubiquitin protein ligase complex inhibitors; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Pituitary ACTH hypersecretion
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in France
  • 06 Jun 2017 Hybrigenics has patnet protection for USP8 inhibitors in Europe
  • 06 Jun 2017 Early research in Pituitary ACTH hypersecretion in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top